Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum

An estimated 40 million women of reproductive age are infected with one of three species of the waterborne parasite Schistosoma spp. Treatment with praziquantel (PZQ) via mass drug administration (MDA) campaigns is the mainstay of schistosomiasis control for populations living in areas of endemicity. The World Health Organization recommends that pregnant and lactating women be included in schistosomiasis MDA programs, and several recent studies have evaluated the safety and efficacy of PZQ use during pregnancy. ABSTRACT An estimated 40 million women of reproductive age are infected with one of three species of the waterborne parasite Schistosoma spp. Treatment with praziquantel (PZQ) via mass drug administration (MDA) campaigns is the mainstay of schistosomiasis control for populations living in areas of endemicity. The World Health Organization recommends that pregnant and lactating women be included in schistosomiasis MDA programs, and several recent studies have evaluated the safety and efficacy of PZQ use during pregnancy. To date, there are no data describing PZQ pharmacokinetics (PK) during pregnancy or among lactating postpartum women. As part of a randomized controlled trial investigating the safety and efficacy of PZQ during human pregnancy, we examined the PK of this therapeutic drug among three distinct cohorts of women infected with S. japonicum in Leyte, Philippines. Specifically, we studied the PK properties of PZQ among early- and late-gestation pregnant women (n = 15 each) and lactating postpartum women (n = 15) with schistosomiasis. We found that women in early pregnancy had increased apparent clearance and lower area-under-the-curve (AUC0–24) values that may be related to physiological changes in drug clearance and/or changes in oral bioavailability. There was no relationship between body weight and apparent clearance. The mean ± standard deviation partition ratio of plasma to breast milk was 0.36. ± 0.13. The estimated median infant PZQ daily dose would be 0.037 mg/kg of body weight ingested from breast milk, which is significantly lower than the dosage required for antischistosomal activity and not known to be harmful to the infant. Our PK data do not support the suggestion to delay breastfeeding 72 h after taking PZQ. Results can help inform future drug efficacy studies in pregnant and lactating women with schistosomiasis.

[1]  R. Pohlke,et al.  Praziquantel , 2021, Reactions Weekly.

[2]  R. Olveda,et al.  Praziquantel for the treatment of schistosomiasis during human pregnancy , 2017, Bulletin of the World Health Organization.

[3]  C. King,et al.  Cross-sectional interview study of fertility, pregnancy, and urogenital schistosomiasis in coastal Kenya: Documented treatment in childhood is associated with reduced odds of subfertility among adult women , 2017, PLoS neglected tropical diseases.

[4]  J. R. Stothard,et al.  Paediatric and maternal schistosomiasis: shifting the paradigms , 2017, British medical bulletin.

[5]  G. Koren,et al.  Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review , 2016, PLoS medicine.

[6]  Ashutosh Kumar Singh,et al.  Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[7]  S. Roberts,et al.  Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy , 2016, mBio.

[8]  R. Olveda,et al.  Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. , 2016, The Lancet. Infectious diseases.

[9]  S. Caritis,et al.  Pharmacokinetics of drugs in pregnancy. , 2015, Seminars in perinatology.

[10]  S. Khoo,et al.  Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies , 2015, The Journal of antimicrobial chemotherapy.

[11]  Maged M. Costantine,et al.  Physiologic and pharmacokinetic changes in pregnancy , 2014, Front. Pharmacol..

[12]  J. Keiser,et al.  The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). , 2014, The Journal of antimicrobial chemotherapy.

[13]  Hyunyoung Jeong,et al.  Isoform-Specific Regulation of Cytochromes P450 Expression by Estradiol and Progesterone , 2013, Drug Metabolism and Disposition.

[14]  Alan Schumitzky,et al.  Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R , 2012, Therapeutic drug monitoring.

[15]  P. Ndhlovu,et al.  A review of female genital schistosomiasis. , 2012, Trends in parasitology.

[16]  Hyunyoung Jeong.  Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes , 2010, Expert opinion on drug metabolism & toxicology.

[17]  I. Kleinschmidt,et al.  Effects of deworming during pregnancy on maternal and perinatal outcomes in Entebbe, Uganda: a randomized controlled trial. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. García,et al.  Simultaneous determination of albendazole metabolites, praziquantel and its metabolite in plasma by high-performance liquid chromatography-electrospray mass spectrometry. , 2007, Journal of pharmaceutical and biomedical analysis.

[19]  G. Anderson.  Using pharmacokinetics to predict the effects of pregnancy and maternal–infant transfer of drugs during lactation , 2006, Expert opinion on drug metabolism & toxicology.

[20]  Luc Kestens,et al.  Human schistosomiasis , 2006, The Lancet.

[21]  K. Stȩpniewska,et al.  Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil , 2003, European Journal of Clinical Pharmacology.

[22]  M. Wongnawa,et al.  Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers , 2002, Clinical pharmacology and therapeutics.

[23]  I. Miyakawa,et al.  The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N‐acetyltransferase activities in humans , 2001, Clinical pharmacology and therapeutics.

[24]  J. Moodley,et al.  Pharmacokinetics of Zidovudine and Lamivudine in Neonates following Coadministration of Oral Doses Every 12 Hours , 2001, Journal of clinical pharmacology.

[25]  P. Harrigan,et al.  Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. , 1998, The Journal of infectious diseases.

[26]  M. Abdel-Bary,et al.  Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. , 1994, The American journal of tropical medicine and hygiene.

[27]  M. E. Mandour,et al.  Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[28]  G. Leopold,et al.  Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes , 1978, European Journal of Clinical Pharmacology.

[29]  Schistosomiasis: number of people treated worldwide in 2014. , 2016, Releve epidemiologique hebdomadaire.

[30]  F. Held,et al.  Quantitative studies on the occurence of praziquantel in milk and plasma of lactating women , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[31]  G. Anderson.  Pregnancy-Induced Changes in Pharmacokinetics , 2005, Clinical pharmacokinetics.